Bright Minds Biosciences Inc.
DRUG
CNSX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -82.94% | 21.72% | -84.33% | -5,907.34% | 106.24% |
| Total Depreciation and Amortization | 15.45% | 6.96% | -26.75% | 1.95% | -68.64% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 67.40% | -23.14% | 240.13% | 143.22% | -1,040.58% |
| Change in Net Operating Assets | -182.61% | 415.42% | -183.95% | -14.05% | -223.65% |
| Cash from Operations | -353.16% | 63.65% | -49.86% | -58.29% | -214.37% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.38% | -1.95% | -4.07% | -3.36% | 0.42% |
| Issuance of Common Stock | -61.47% | 411,377.27% | -96.48% | -99.50% | 16,519,600.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 81.29% | -- | -- | -100.00% | -- |
| Cash from Financing | -60.29% | 198,381.97% | -107.77% | -99.58% | 214,993.64% |
| Foreign Exchange rate Adjustments | -168.11% | 31.13% | -4,666.67% | -101.00% | 9,445.08% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -80.76% | 837.67% | -100.85% | -104.14% | 10,913.32% |